Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.

Abstract: The invention provides compositions and methods for effective lysosomal targeting mediated by SORT1. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Sanfilippo syndrome type B.

Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.

Abstract: A headache can be treated effectively by administration of a botulinum toxin to a patient at specific muscles using specific doses.

Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.

Abstract: The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (Fcp1)-deficient Leptospira bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (Fcp1)-deficient Leptospira bacterium. Another aspect includes a composition comprising a flagellar-coiling protein 1 (Fcp1) deficient Leptospira bacterium. Yet another aspect includes a method of producing a motility-deficient Leptospira bacterium comprising inhibiting expression of a wild-type flagellar-coiling protein 1 (Fcp1) gene. Methods of stimulating an immune response and reducing or treating an infectious disease caused by one or more Leptospira bacteria in a subject in need thereof comprising administering a composition comprising an effective amount of flagellar-coiling protein 1 (Fcp1) deficient Leptospira bacteria to the subject are also included.

Abstract: The present invention provides attenuated P. multocida strains that elicit an immune response in animal P. multocida, compositions comprising said strains, methods of vaccination against P. multocida, and kits for use with such methods and compositions. The invention further provides novel, genetically-engineered mutations in P. multocida hyaD and nanPU genes, which are useful in the production of novel attenuated P. multocida bacterial strains.

Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.

Abstract: A method of preventing, controlling or treating CMV infections with a vaccine comprising an immunologically effective amount of a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.

Abstract: Compositions and methods for the treatment of allergic disease include treating a subject in need thereof with a dosage of an allergen, wherein the allergen is administered to the subject's oral vestibular space. In a preferred embodiment, the allergen is administered at night, thereby exploiting circadian rhythms in the subject's immune response and enhancing the effectiveness of the treatment.

Abstract: Provided are a composition and a food or drink, having the effect of enhancing an immune response to an antigen, which is administered by another route such as subcutaneous injection, by orally administering to a subject, lactic acid bacteria, a culture thereof, a treated product thereof, or a composition comprising the same. An oral ingestion composition, which comprises a lactic acid bacterium strain that is Lactococcus lactis subsp. lactis enhancing the proliferation of cytotoxic T lymphocytes (CTL) and the generation of antibodies, or a culture or treated product thereof, and is used in combination with an antigen as a vaccine, wherein the oral ingestion composition is for use in enhancing the proliferation of cytotoxic T lymphocytes (CTL) specific to the antigen and the generation of antibodies specific to the antigen.

Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.

Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

Abstract: The invention provides a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising extracellular domain disclosed herein. Some aspects of the invention relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising the extracellular domain disclosed herein. Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.

Abstract: This invention relates to novel nanocompounds that are cytotoxic to tumor cells when combined with ultraviolet light, the nanocompounds comprising multilayered carbon nanotubes with anatase-phase titanium dioxide or anatase-phase titanium dioxide and folate. The invention also relates to a composition containing said nanocompounds and to a method for the treatment of cancer; comprising the administration of said composition in co-treatment with UV radiation. The invention further relates to a method for the synthesis of the nano-compounds.

Abstract: The present invention relates to ophthalmic compositions for treatment of conditions in the eye. More specifically, the present invention relates to ophthalmic compositions comprising a polyquaternium compound and an anionic polymer. Methods for reducing and/or preventing the incompatibility of polyquaternium compounds with anionic polymers are also disclosed.

Abstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.

Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.

Abstract: The present disclosure is directed methods and products for synthesizing and using targeted templated assembly reactants comprising at least one nucleic acid recognition moiety, at least one selectively-reactive moiety, and at least one effector partial moiety. The nucleic acid recognition moiety can bind a target nucleic acid sequence within a sample. The nucleic acid recognition moiety also can bind the selectively-reactive moiety. Additionally, the effector partial moiety can bind the selectively-reactive moiety to produce an active effector structure. Also disclosed are methods of delivering the targeted templated assembly reactants and active effector structures formed from the targeted templated assembly reactants.

Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.

Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Abstract: A method includes: (1) applying stimulations to a system, wherein applying the stimulations includes modulating, over time, characteristics of the stimulations; (2) measuring a time-varying response of the system to the stimulations; (3) fitting the time-varying response of the system into a model of the system; and (4) using the model of the system, identifying an optimized combination of characteristics of the stimulations to yield a desired response of the system.

Abstract: A sanitizing device for sanitizing a chestpiece of a stethoscope connected to at least one earpiece by a tube, the sanitizing device being composed of: a housing composed of two housing halves and a hinge assembly connecting the housing halves together to permit relative pivotal movement between the housing halves between a closed state in which the housing halves enclose a closed space, and an open state; and a source of sanitizing radiation disposed to irradiate the closed space. The housing is provided with an opening for receiving the tube; the opening is composed of two opening portions each formed in a respective housing half; and the hinge assembly is composed of two hinge portions each forming part of a respective housing half, the hinge portions being separable from one another to allow the chestpiece to be placed in the closed space.

Abstract: Dialysis monitors capable of storing and using thermal energy and methods related thereto are disclosed. Dialysis monitors capable of storing and using disinfection and/or cleaning fluids which was used at an earlier disinfection and/or cleaning event and methods related thereto are also disclosed. Thermally stored energy may, for example, be used for quick thermal disinfection of the fluid path, quick start-up of the preparation of treatment fluid, and as back-up power for continuous preparation of treatment fluid should externally provided power be interrupted.

Abstract: According to an aspect of the invention, an indwelling catheter is provided which comprises a catheter shaft. The catheter either comprises a light source or is adapted to receive light from a light source, and is configured such that light is transmitted from the light source into the catheter shaft. Moreover, the catheter shaft is formed of a polymeric material that transmits a quantity of light from the light source that is effective to inactivate microorganisms on a surface of the catheter shaft upon activation of the light source. For example, the light may inactivate the microorganisms directly or in conjunction with a photosensitizer. According to another aspect of the invention, a sterilization method is provided, which comprises activating the light source while the catheter is inserted in a subject.

Abstract: Provided herein are portable ultraviolet (UV) devices, systems, and methods of use and manufacturing same. Methods of use include methods for UV disinfection and sterilization, more specifically, methods for UV disinfection and sterilization of a container, a room, a space or a defined environment. The portable UV devices, systems and methods are particularly useful for the UV disinfection and sterilization of a container, a room, a space or defined environment used in the food, beverage and dairy industry and in the process of fermentation for an alcoholic beverage. Provided are also portable UV devices, systems, and methods for inhibiting the growth of one or more species of microorganisms present in a container, a room, a space or a defined environment, preferably for inhibiting the growth of one or more species of microorganisms present on an interior surface of a container, a room, a space or a defined environment.

Abstract: A fluid sterilization device includes: a straight tube that defines a processing flow passage; a light source that radiates ultraviolet light toward the processing flow passage in an axial direction of the straight tube; and a light receiving part that receives a portion of the ultraviolet light output from the light source. The straight tube is made of a fluororesin. The straight tube includes a recess formed in a part of an outer wall surface of the straight tube such that a thin part is partly provided in the straight tube. The thin part has a radial thickness from an inner wall surface of the straight tube that is smaller than a thickness in other parts. The light receiving part is provided in the recess to receive the ultraviolet light transmitted through the thin part.

Abstract: The present disclosure relates to methods and system for disinfecting surfaces within a volumetric space by forming peracids in a reaction layer in situ directly on the surfaces to be disinfected. Particularly, a peroxide compound and an organic acid are sequentially dispersed into the volumetric space, preventing peracids from being formed until the two reactants contact each other on the surface to be disinfected. In some embodiments, any of the dispersed aqueous compositions can optionally be electrostatically charged. Additionally, a system for sequentially dispersing the peracid reactant compounds by electrostatic spraying is provided.

Abstract: An agent for removing malodor from a painting booth includes a volatile organic compound (VOC) degrading microorganism and a volatile fatty acid (VFA) degrading microorganism. The VOC degrading microorganism is configured to degrade VOC. The VFA degrading microorganism is configured to degrade VFA generated when the VOC is degraded. A method of removing malodor is also disclosed.

Abstract: A diffuser includes a base, a fan mounted to the base, a receptacle provided over the fan and mounted to the base, a sleeve mounted on the upper surface of the base and enclosing the fan and receptacle, and a lid mounted over the sleeve. Each of the base and the lid comprises at least one opening formed about a periphery thereof. The receptacle comprises a bottom wall with a plurality of opening formed therethrough and a vertically extending sidewall to retain a fragrant medium therein. The fan forces airflow from an exterior of the diffuser, into the base through the at least one opening, through the plurality of openings formed in the bottom wall of the receptacle, through the receptacle and about any fragrant medium therein, into a volume of space above the receptacle enclosed by the lid, and out through the at least one opening in the lid.

Abstract: A fragrance delivery apparatus contains: a body, a fan, a power base, and a case. The body includes an accommodation chamber defined therein, a receiving groove formed above the accommodation chamber, an air vent arranged on a first side of the body and communicating between the accommodation chamber and the receiving groove, and multiple elongated orifices formed on a second side of the body opposite to the first side of the body and communicating with the accommodation chamber. The fan is accommodated in the accommodation chamber and draws external gas from the multiple elongated orifices. The power base is connected with the body and shields the accommodation chamber, and the power base is configured to supply power and is electrically connected with the fan. The case is removably connected outside the body and includes a spray nozzle which is in communication with the receiving groove.

Abstract: The disclosure herein concerns a method including receiving at a computer at least one target value of a scent parameter for an environment that is remote from the computer, receiving at the computer a sensed parameter of the environment, and controlling, via the computer, diffusion of a liquid from a source of the liquid in fluid communication with at least one scent diffusion device to achieve the target value of the scent parameter, wherein controlling includes setting or adjusting an operation parameter of the at least one scent diffusion device in response to the sensed parameter.

Abstract: The present invention relates to skin dressings that are useful in the treatment of conditions associated with tissue ischaemia and skin lesions including those that are infected, such as burns and surgical wounds and chronic wounds such as but not limited5 to diabetic foot ulcers and venous leg ulcers. The skin dressings are also useful to effect transdermal delivery of pharmaceutically active agents.

Abstract: This invention claims hot melt adhesive compositions that can be used to form elastic composites that are useful in disposable absorbent articles. The compositions have good elastic recovery and high peel adhesion at a viscosity of less than about 20,000 cps at 177° C. The low viscosity makes it possible to apply the adhesive at a high line speed and target application to only those areas requiring elastic performance.

Abstract: The embodiments relate to an injectable composition for a bone cement material comprising a dry powder component, a liquid component and a modifier configured to modify a Young's modulus of the bone cement material. The modifier is linoleic acid or a derivative thereof and is present in a concentration of 0.1 to 12 v/v of the liquid component.

Abstract: The present invention relates to a phosphazene-based polymer comprising an amino acid ester, polyethylene glycol, a group comprising a functional group, and a catechol group linked directly or by a linker to a part of or an entire functional group, in a predetermined ratio. In addition, the present invention relates to a preparation method thereof, and a tissue-adhesive composition comprising the same as an active ingredient.

Abstract: Film forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film forming polymer, a tackifier, and a volatile solvent. The film forming gels can also include antiseptics, cationic polymer coagulants, fillers, and other additives. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing.

Abstract: Described herein are preparations and applications of gellan gum hydrogel for cell culture and biomedical applications, including 2D coating culture, 3D cell culture, and injection. The gellan gum materials for such application include water soluble low acyl gellan gum, high acyl gellan gum, modified gellan gum and a mixture of gellan gum mixture with other chemical/biological molecules.

Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.

Abstract: A biocompatible tissue repair implant or scaffold device is provided for use in repairing a variety of tissue injuries, particularly injuries to cartilage, ligaments, tendons, and nerves. The repair procedures may be conducted with implants that contain a biological component that assists in healing or tissue repair. The biocompatible tissue repair implants include a biocompatible scaffold and particles of living tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold.

Abstract: A bone void filler material is provided for sustained release of a therapeutic agent. The bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate, and ceramic particles disposed within the matrix. The ceramic cement beads are loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.

Abstract: A complex of implant and cultured periodontal ligament cell sheet, that can be satisfactorily stabilized into the bone through periodontal ligament tissue, is provided. A fixture of the inserted implant is coated with calcium phosphate and the cultured periodontal ligament cell sheet is brought into intimate contact with the implant.

Abstract: The invention relates to an implant preform made of plastic, which comprises an assembly of at least one biocompatible—being intended for contact with a biological material—thermoplastic plastics unit (A) having an elasticity modulus EA and at least one thermoplastic plastics unit (B) having an elasticity modulus EB, where for the elasticity moduli of these plastics units EA<EB, and the plastics units in their assembly zone are seamlessly connected thermally to one another. The invention also relates to the production of the implant preform made of plastic and also to the use of the implant preform as an implant or for fabrication of an implant therefrom, more particularly to the use thereof as a dental implant or for fabrication of a dental implant. The invention can also be applied to other bone implants.

Abstract: Novel hybrid materials and fabrication methods thereof are provided. The novel hybrid materials can include a biodegradable polymer and a biodegradable metallic material. The hybrid material can also include a coupling agent between the biodegradable metallic material and the biodegradable polymer. A method of fabricating a hybrid material can include performing a surface treatment process on the biodegradable metallic material, and then either performing a solvent formation method or a thermal formation method.

Abstract: An inventive digestive tract barrier includes a material defining dimensions of a tube sized to deploy within the digestive tract of a subject. The material or stitches that make up the barrier disintegrate in a controlled manner. The disintegration precludes the need for a surgical procedure to retrieve the barrier and allows for increased nutritional absorption after behavior modification has occurred. Through the inclusion of opening or fenestrations in the barrier, bile flow and nutrition absorption are facilitated. Disintegration is facilitated by formation of the barrier from biodegradable material, stitching non-degradable swatches with disintegrating stitching, or the use of a MEMS cutter. A digestive barrier coated on either the interior or exterior of the tube facilitates management of conditions such as obesity, colitis, and Crohn's disease.